Neuroserpin: a selective inhibitor of tissue-type plasminogen activator in the central nervous system

Summary

Neuroserpin is a member of the serine proteinase inhibitor (serpin) gene family that reacts preferentially with tissue-type plasminogen activator (tPA) and is primarily localized to neurons in regions of the brain where tPA is also found. Outside of the central nervous system (CNS) tPA is predominantly found in the blood where its primary function is as a thrombolytic enzyme. However, tPA is also expressed within the CNS where it has a very different function, promoting events associated not only with synaptic plasticity but also with cell death in a number of settings, such as cerebral ischemia and seizures. Neuroserpin is released from neurons in response to neuronal depolarization and plays an important role in the development of synaptic plasticity. Following the onset of cerebral ischemia there is an increase in both tPA activity and neuroserpin expression in the area surrounding the necrotic core (ischemic penumbra), and treatment with neuroserpin following ischemic stroke or overexpression of the neuroserpin gene results in a significant decrease in the volume of the ischemic area as well as in the number of apoptotic cells. TPA activity and neuroserpin expression are also increased in specific areas of the brain by seizures, and treatment with neuroserpin slows the progression of seizure activity throughout the CNS and results in significant neuronal survival in the hippocampus. Mutations in human neuroserpin result in a form of autosomal dominant inherited dementia which is characterized by the presence of intraneuronal inclusion bodies and is known as Familial Encephalopathy with Neuroserpin Inclusion Bodies.

Keywords

Neuroserpin - tissue-type plasminogen activator - cerebral ischemia - seizures - dementia

• References

• 1 Sappino AP, Madani R, Huarte J. et al. Extracellular proteolysis in the adult murine brain. J Clin Invest 1993; 92: 679-85.
• 2 Carroll PM, Tsirka SE, Richards WG. et al. The mouse tissue plasminogen activator gene 5’ flanking region directs appropriate expression in development and a seizure-enhanced response in the CNS. Development 1994; 120: 3173-83.
• 3 Qian Z, Gilbert ME, Colicos MA. et al. Tissue plasminogen activator is induced as an immediate-early gene during seizure, kindling and longterm potentiation. Nature 1993; 361: 453-7.
• 4 Seeds NW, Williams BL, Bickford PC. Tissue plasminogen activator induction in Purkinje neurons after cerebellar motor learning. Science 1995; 270: 1992-4.
• 5 Yepes M, Sandkvist M, Coleman TA. et al. Regulation of seizure spreading by neuroserpin and tissue-type plasminogen activator is plasminogen-independent. J Clin Invest 2002; 109: 1571-8.
• 6 Hunt LT, Dayhoff MO. A surprising new protein superfamily containing ovalbumin, antithrombin-III, and alpha 1-proteinase inhibitor. Biochem Biophys Res Commun 1980; 95: 864-71.
• 7 Gettins PGW, Patston PA, Olson ST. Serpins: Structure, Function and Biology. R.G. Landes Company; NY, NY: 1-202 1996
• 8 Vassalli JD, Sappino AP, Belin D. The plasminogen activator/plasmin system. J Clin Invest 1991; 88: 1067-72.
• 9 Fell B, Smith AM, Hill RM. et al. Characterisation of two serine protease inhibitors expressed in the pituitary gland. Arch Physiol Biochem 2002; 110: 26-33.
• 10 Houenou LJ, Turner PL, Li L. et al. A serine protease inhibitor, protease nexin I, rescues motoneurons from naturally occurring and axotomy-induced cell death. Proc Natl Acad Sci USA 1995; 92: 895-9.
• 11 Vaughan PJ, Pike CJ, Cotman CW. et al. Thrombin receptor activation protects neurons and astrocytes from cell death produced by environmental insults. J Neurosci 1995; 15: 5389-401.
• 12 Carrell RW, Gooptu B. Conformational changes and disease—serpins, prions and Alzheimer’s. Curr Opin Struct Biol 1998; 08: 799-809.
• 13 Carrell RW, Lomas DA. Conformational disease. Lancet 1997; 350: 134-8.
• 14 Miller RJ, Roos RP. What happens when mutant neuroserpins get into bad shape. Lancet 2000; 355: 590-1.
• 15 Lawrence DA, Strandberg L, Ericson J. Structure-function studies of the SERPIN plasminogen activator inhibitor type 1. Analysis of chimeric strained loop mutants. J Biol Chem 1990; 265: 20293-301.
• 16 Lawrence DA, Ginsburg D, Day DE. et al. Serpin-protease complexes are trapped as stable acyl-enzyme intermediates. J Biol Chem 1995; 270: 25309-12.
• 17 Huntington JA, Read RJ, Carrell RW. Structure of a serpin-protease complex shows inhibition by deformation. Nature 2000; 407: 923-6.
• 18 Osterwalder T, Contartese J, Stoeckli ET. et al. Neuroserpin, an axonally secreted serine protease inhibitor. EMBO J 1996; 15: 2944-53.
• 19 Hastings GA, Coleman TA, Haudenschild CC. et al. Neuroserpin, a brain-associated inhibitor of tissue plasminogen activator is localized primarily in neurons. Implications for the regulation of motor learning and neuronal survival. J Biol Chem 1997; 272: 33062-7.
• 20 Schrimpf SP, Bleiker AJ, Brecevic L. et al. Human neuroserpin (PI12): cDNA cloning and chromosomal localization to 3q26. Genomics 1997; 40: 55-62.
• 21 Osterwalder T, Cinelli P, Baici A. et al. The axonally secreted serine proteinase inhibitor, neuroserpin, inhibits plasminogen activators and plasmin but not thrombin. J Biol Chem 1998; 273: 2312-21.
• 22 Berger P, Kozlov SV, Krueger SR. et al. Structure of the mouse gene for the serine protease inhibitor neuroserpin (PI12). Gene 1998; 214: 25-33.
• 23 Chang WS, Chang NT, Lin SC. et al. Tissuespecific cancer-related serpin gene cluster at human chromosome band 3q26. Genes Chromosomes Cancer 2000; 29: 240-55.
• 24 Krueger SR, Ghisu GP, Cinelli P. et al. Expression of neuroserpin, an inhibitor of tissue plasminogen activator, in the developing and adult nervous system of the mouse. J Neurosci 1997; 17: 8984-96.
• 25 Hill RM, Parmar PK, Coates LC. et al. Neuroserpin is expressed in the pituitary and adrenal glands and induces the extension of neurite-like processes in AtT-20 cells. Biochem J 2000; 345 Pt 3: 595-601.
• 26 Atchley WR, Lokot T, Wollenberg K. et al. Phylogenetic analyses of amino acid variation in the serpin proteins. Mol Biol Evol 2001; 18: 1502-11.
• 27 Barker-Carlson K, Lawrence DA, Schwartz BS. Acyl-enzyme complexes between tissuetype plasminogen activator and neuroserpin are short-lived in vitro. J Biol Chem 2002; 277: 46852-7.
• 28 Cinelli P, Madani R, Tsuzuki N. et al. Neuroserpin, a neuroprotective factor in focal ischemic stroke. Mol Cell Neurosci 2001; 18: 443-57.
• 29 Sawdey MS, Loskutoff DJ. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest 1991; 88: 1346-53.
• 30 Mansuy IM, van der Putten H, Schmid P. et al. Variable and multiple expression of Protease Nexin-1 during mouse organogenesis and nervous system development. Development 1993; 119: 1119-34.
• 31 Hook V, Metz-Boutigue MH. Protein trafficking to chromaffin granules and proteolytic processing within regulated secretory vesicles of neuroendocrine chromaffin cells. Ann NY Acad Sci 2002; 971: 397-405.
• 32 Hill RM, Coates LC, Parmar PK. et al. Expression and functional characterization of the serine protease inhibitor neuroserpin in endocrine cells. Ann NY Acad Sci 2002; 971: 406-15.
• 33 Krystosek A, Seeds NW. Plasminogen activator release at the neuronal growth cone. Science 1981; 213: 1532-4.
• 34 Krystosek A, Seeds NW. Plasminogen activator secretion by granule neurons in cultures of developing cerebellum. Proc Natl Acad Sci USA 1981; 78: 7810-4.
• 35 Krystosek A, Seeds NW. Normal and malignant cells, including neurons, deposit plasminogen activator on the growth substrata. Exp Cell Res 1986; 166: 31-46.
• 36 Dent MA, Sumi Y, Morris RJ. et al. Urokinase-type plasminogen activator expression by neurons and oligodendrocytes during process outgrowth in developing rat brain. Eur J Neurosci 1993; 05: 633-47.
• 37 Sumi Y, Dent MA, Owen DE. et al. The expression of tissue and urokinase-type plasminogen activators in neural development suggests different modes of proteolytic involvement in neuronal growth. Development 1992; 116: 625-37.
• 38 Hantai D, Rao JS, Kahler C. et al. Decrease in plasminogen activator correlates with synapse elimination during neonatal development of mouse skeletal muscle. Proc Natl Acad Sci USA 1989; 86: 362-6.
• 39 Stoeckli ET, Lemkin PF, Kuhn TB. et al. Identification of proteins secreted from axons of embryonic dorsal-root-ganglia neurons. Eur J Biochem 1989; 180: 249-58.
• 40 Parmar PK, Coates LC, Pearson JF. et al. Neuroserpin regulates neurite outgrowth in nerve growth factor-treated PC12 cells. J Neurochem 2002; 82: 1406-15.
• 41 Berger P, Kozlov SV, Cinelli P. et al. Neuronal depolarization enhances the transcription of the neuronal serine protease inhibitor neuroserpin. Mol Cell Neurosci 1999; 14: 455-67.
• 42 Wannier-Morino P, Rager G, Sonderegger P. et al. Expression of neuroserpin in the visual cortex of the mouse during the developmental critical period. Eur J Neurosci 2003; 17: 1853-60.
• 43 Makarova A, Mikhailenko I, Bugge TH. et al. The LDL receptor-related protein modulates protease activity in the brain by mediating the cellular internalization of both neuroserpin and neuroserpin: tPA complexes. J Biol Chem 2003; 278: 50250-28.
• 44 Madani R, Kozlov S, Akhmedov A. et al. Impaired explorative behavior and neophobia in genetically modified mice lacking or overexpressing the extracellular serine protease inhibitor neuroserpin. Mol Cell Neurosci 2003; 23: 473-94.
• 45 Mutations in the neuroserpin gene are rare in familial dementia. French Alzheimer’s Disease and Fronto-Temporal Dementia Genetics Study Groups. Ann Neurol 2000; 47: 688.
• 46 Takao M, Benson MD, Murrell JR. et al. Neuroserpin mutation S52R causes neuroserpin accumulation in neurons and is associated with progressive myoclonus epilepsy. J Neuropathol Exp Neurol 2000; 59: 1070-86.
• 47 Yazaki M, Liepnieks JJ, Murrell JR. et al. Biochemical characterization of a neuroserpin variant associated with hereditary dementia. Am J Pathol 2001; 158: 227-33.
• 48 Finckh U, Muller-Thomsen T, Mann U. et al. High frequency of mutations in four different disease genes in early-onset dementia. Ann NY Acad Sci 2000; 920: 100-6.
• 49 Bradshaw CB, Davis RL, Shrimpton AE. et al. Cognitive deficits associated with a recently reported familial neurodegenerative disease: familial encephalopathy with neuroserpin inclusion bodies. Arch Neurol 2001; 58: 1429-34.
• 50 Belorgey D, Crowther DC, Mahadeva R. et al. Mutant Neuroserpin (S49P) that causes familial encephalopathy with neuroserpin inclusion bodies is a poor proteinase inhibitor and readily forms polymers in vitro. J Biol Chem 2002; 277: 17367-73.
• 51 Filla A, De Michele G, Cocuzza S. et al. Early onset autosomal dominant dementia with ataxia, extrapyramidal features, and epilepsy. Neurology 2002; 58: 922-8.
• 52 Lomas DA, Carrell RW. Serpinopathies and the conformational dementias. Nat Rev Genet 2002; 03: 759-68.
• 53 Davis RL, Shrimpton AE, Carrell RW. et al. Association between conformational mutations in neuroserpin and onset and severity of dementia. Lancet 2002; 359: 2242-7.
• 54 Crowther DC. Familial conformational diseases and dementias. Hum Mutat 2002; 20: 1-14.
• 55 Benvenga S. Conformational mutations in neuroserpin and familial dementias. Lancet 2002; 360: 1696.
• 56 Yepes M, Sandkvist M, Wong MK. et al. Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis. Blood 2000; 96: 569-76.
• 57 Zhang Z, Zhang L, Yepes M. et al. Adjuvant treatment with neuroserpin increases the therapeutic window for tissue-type plasminogen activator administration in a rat model of embolic stroke. Circulation 2002; 106: 740-5.
• 58 Yepes M, Sandkvist M, Moore EG. et al. Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest 2003; 112: 1533-40.
• 59 Gveric D, Herrera B, Petzold A. et al. Impaired fibrinolysis in multiple sclerosis: a role for tissue plasminogen activator inhibitors. Brain 2003; 126: 1590-8.
• 60 Hakak Y, Walker JR, Li C. et al. Genome-wide expression analysis reveals dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci USA 2001; 98: 4746-51.
• 61 Davis RL, Holohan PD, Shrimpton AE. et al. Familial encephalopathy with neuroserpin inclusion bodies. Am J Pathol 1999; 155: 1901-13.
• 62 Davis RL, Shrimpton AE, Holohan PD. et al. Familial dementia caused by polymerization of mutant neuroserpin. Nature 1999; 401: 376-9.
• 63 Davis RL, Shrimpton AE, Carrell RW. et al. Association between conformational mutations in neuroserpin and onset and severity of dementia. Lancet 2002; 359: 2242-7.
• 64 Hakim AM. The cerebral ischemic penumbra. Can J Neurol Sci 1987; 14: 557-9.
• 65 Hossmann KA. 1994; Viability thresholds and the penumbra of focal ischemia. Ann Neurol 36: 557-65.
• 66 Symon L. The relationship between CBF, evoked potentials and the clinical features in cerebral ischaemia. Acta Neurol Scand Suppl 1987; 78: 175-90.
• 67 Wang YF, Tsirka SE, Strickland S. et al. Tissue plasminogen activator (tPA) increases neuronal damage after focal cerebral ischemia in wild-type and tPA-deficient mice. Nat Med 1998; 04: 228-31.
• 68 Nagai N, De Mol M, Lijnen HR. et al. Role of plasminogen system components in focal cerebral ischemic infarction: a gene targeting and gene transfer study in mice. Circulation 1999; 99: 2440-4.
• 69 Tsirka SE, Gualandris A, Amaral DG. et al. Excitotoxin-induced neuronal degeneration and seizure are mediated by tissue plasminogen activator. Nature 1995; 377: 340-4.
• 70 Tsirka SE, Rogove AD, Bugge TH. et al. An extracellular proteolytic cascade promotes neuronal degeneration in the mouse hippocampus. J Neurosci 1997; 17: 543-52.
• 71 Ben Ari Y, Represa A. Brief seizure episodes induce long-term potentiation and mossy fibre sprouting in the hippocampus. Trends Neurosci 1990; 13: 312-8.
• 72 Gall CM, Lauterborn JC, Guthrie KM. et al. Seizures and the regulation of neurotrophic factor expression: associations with structural plasticity in epilepsy. Adv Neurol 1997; 72: 9-24.
• 73 Gualandris A, Jones TE, Strickland S. et al. Membrane depolarization induces calciumdependent secretion of tissue plasminogen activator. J Neurosci 1996; 16: 2220-5.
• 74 Baranes D, Lederfein D, Huang YY. et al. Tissue plasminogen activator contributes to the late phase of LTP and to synaptic growth in the hippocampal mossy fiber pathway. Neuron 1998; 21: 813-25.
• 75 Parmer RJ, Mahata M, Mahata S. et al. Tissue plasminogen activator (t-PA) is targeted to the regulated secretory pathway. Catecholamine storage vesicles as a reservoir for the rapid release of t-PA. J Biol Chem 1997; 272: 1976-82.